xref Your response will be removed from the review this cannot be undone. 0000002307 00000 n With your consent, we may also use third party cookies to analyze your usage of the website. ET on February 18, 2022 by dialing in the U.S. toll free 888-203-1112 or international +1 719-457-0820, confirmation code: 2150568. hb```b``{Ab,GU\r``8e/Gu sMJM ;xxDFD>]/=nxoEA2nlt2Tr2\+lcGC=!Rq(t=-SPMHj>Ytv@! 0000042788 00000 n I'm a new hire. Selling, General & Admin. And while our work transforms the lives of patients, it also transforms the lives and careers of those who do it. Your response will be removed from the review this cannot be undone. You may read any reports, statements or other information filed by the company or Turning Point Therapeutics with the SEC at no charge on the SECs website at www.sec.gov. Learn about Bristol Myers Squibb Vacation & Paid Time Off, including a description from the employer, and comments and ratings provided anonymously by current and former Bristol Myers Squibb employees. If, like us, you believe in the power of science to address some of the most challenging diseases of our time, then youll fit right in as we search for the next breakthroughs in biopharma. Media: media@bms.com Minor Holidays . 0000014201 00000 n Such risks, uncertainties and other matters include, but are not limited to: increasing pricing pressures from market access, pharmaceutical pricing controls and discounting; changes to tax and importation laws and other restrictions in the United States, the European Union and other regions around the world that result in lower prices, lower reimbursement rates and smaller populations for whom payers will reimburse; changes under the 340B Drug Pricing Program; challenges inherent in new product development, including obtaining and maintaining regulatory approval; the companys ability to obtain and protect market exclusivity rights and enforce patents and other intellectual property rights; the possibility of difficulties and delays in product introduction and commercialization; the risk of certain novel approaches to disease treatment (such as CAR T therapy); industry competition from other manufacturers; potential difficulties, delays and disruptions in manufacturing, distribution or sale of products, including without limitation, interruptions caused by damage to the companys and the companys suppliers manufacturing sites; the impact of integrating the companys and Celgenes business and operations, including with respect to human capital management, portfolio rationalization, finance and accounting systems, sales operations and product distribution, pricing systems and methodologies, data security systems, compliance programs and internal controls processes; the risk of an adverse patent litigation decision or settlement and exposure to other litigation and/or regulatory actions; the impact of any healthcare reform and legislation or regulatory action in the United States and international markets; increasing market penetration of lower-priced generic products; the failure of the companys suppliers, vendors, outsourcing partners, alliance partners and other third parties to meet their contractual, regulatory and other obligations; regulatory decisions impacting labeling, manufacturing processes and/or other matters; the impact on the companys competitive position from counterfeit or unregistered versions of its products or stolen products; the adverse impact of cyber-attacks on the companys information systems or products, including unauthorized disclosure of trade secrets or other confidential data stored in the companys information systems and networks; the companys ability to execute its financial, strategic and operational plans; the companys ability to identify potential strategic acquisitions, licensing opportunities or other beneficial transactions; the companys dependency on several key products; any decline in the companys future royalty streams; the companys ability to effectively manage acquisitions, divestitures, alliances and other portfolio actions and to successfully realize the expected benefits of such actions; the companys ability to attract and retain key personnel; the impact of the companys significant additional indebtedness that it incurred in connection with the Celgene acquisition and the MyoKardia acquisition; political and financial instability of international economies and sovereign risk; interest rate and currency exchange rate fluctuations, credit and foreign exchange risk management; the impact of adverse outcomes in lawsuits, claims, proceedings and government investigations; the impact of our exclusive forum provision in our by-laws for certain lawsuits on our stockholders ability to obtain a judicial forum that it finds favorable for such lawsuits; issuance of new or revised accounting standards; and risks relating to public health outbreaks, epidemics and pandemics, including the impact of the COVID-19 pandemic on the companys operations. The information contained on, or that may be accessed through, our website or social media channels are not incorporated by reference into, and are not a part of, this document. Usually give off For the year end holidays too! Namely, we are not able to reliably predict the impact of specified items or currency exchange rates beyond the next twelve months. Certain other significant tax items are also excluded such as the impact resulting from internal transfers due to streamlining our legal entity structure subsequent to the Celgene acquisition and the global intangible low taxed income tax change upon finalization of the Otezla* divestiture in 2020. We may use this website as a means of disclosing material, non-public information and for complying with our disclosure obligations under Regulation FD. I am confident in our ability to execute against key milestones in 2022, including three planned first-in-class launches with the fixed dose combination of relatlimab plus nivolumab, mavacamten and deucravacitinib. With repotrectinib, we have the opportunity to change the standard of care and address a significant unmet medical need for ROS1-positive non-small cell lung cancer patients., Through this transaction, we will be able to harness the full potential of our precision oncology platform to advance the standard of care for cancer patients. Copyright 20082023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. Former Sales Training Manager in nullnull, Current Senior Manufacturing Engineer in New Brunswick, NJ, New Jersey, Former Senior Financial Analyst in Princeton, NJ, New Jersey, Current Senior Cell Processing Specialist in Summit, NJ, New Jersey, Current Scientific Director in Princeton, NJ, New Jersey, Current Statistician in New Brunswick, NJ, New Jersey, Current Sourcing Manager in Tampa, FL, Florida. In addition, the financial guidance provided in this release relies on assumptions about the duration and severity of the COVID-19 pandemic, timing of the return to a more stable business environment, patient and physician behaviors, buying patterns and clinical trial activities, which may prove to be incorrect. Our broad range of benefits opportunities can enrich your total rewards experience and financial readiness to take on whatever is next in your life: Our paid vacation and holidays give you the flexibility to take time off to recharge and return refreshed and invigorated to deliver your best: Theres more to a healthy person than a healthy body. Normal for industry. This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell securities, nor is it a substitute for the tender offer materials that Bristol Myers Squibb and Rhumba Merger Sub Inc. (Merger Sub) will file with the U.S. Securities and Exchange Commission (SEC). We routinely post important information for investors on our website, BMS.com, in the Investors section. Cautionary Statement Regarding Forward-Looking Statements. Apr 27, 2021 (The Expresswire) -- Covid -19 Impact to global Stroke Treatment Drugs Market for 2015-2025. Turning Point Therapeutics Board of Directors unanimously recommends that Turning Point Therapeutics shareholders tender their shares in the tender offer. Job security always hanging over your head. Bristol ups aid. 0000043107 00000 n The accurate completion of reimbursement- or coverage-related documentation is the responsibility of the healthcare provider and patient. Holiday Calendar; Earnings Calendar; A sign stands outside a Bristol Myers Squibb facility in Cambridge, Massachusetts, U.S., May 20, 2021. 0000007493 00000 n Forward-looking statements in this earnings release should be evaluated together with the many risks and uncertainties that affect the companys business and market, particularly those identified in the cautionary statement and risk factors discussion in the companys Annual Report on Form 10-K for the year ended December 31, 2020, as updated by the companys subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the Securities and Exchange Commission. Bristol Myers (BMY) Earnings Date & Reports 8,681 Followers Portfolio Earnings Data Report Date Apr 27, 2023 Before Open Not Confirmed Period Ending 2023 (Q1) Consensus EPS Forecast $1.98 Last Year's EPS $1.96 Same Quarter Last Year Analyst Consensus Moderate Buy Based on 9 Analysts Ratings Bristol Myers (BMY) Earnings, Revenues Date & History The performance of key suppliers is monitored regularly. Gregorian year (common era) Hebrew year. Bristol-Myers Squibb Co (BMY) Stock Price & News - Google Finance Home BMY NYSE Bristol-Myers Squibb Co Follow Share $69.30 After Hours: $69.30 (0.00%) 0.00 Closed: Mar 3, 4:02:47 PM GMT-5. Moving to the bottom line, Bristol Myers Squibb grew its non-GAAP EPS by 22.7% YOY to $2.00 in the third quarter. Turning Point Therapeutics I'm ready to enroll! though we are required to work bank holidays, Paid holidays for employees are always offered, they add weeks off at times. Media and Investor Relations: ir@tptherapeutics.com, Bristol Myers Squibb to Acquire Turning Point Therapeutics, a Leading Precision Oncology Company. 0000008852 00000 n Bristol Myers Squibb is introducing its 2022 GAAP EPS guidance range of $3.37 - $3.67 and reaffirming its non-GAAP EPS guidance range of $7.65 - $7.95. 0000008372 00000 n During a conference call at 9 a.m. Shares of Bristol Myers Squibb Co. BMY, +0.36% shed 2.1% in premarket trading Thursday, after the drug maker reported a first-quarter profit that BMY AGEN. %%EOF BMY: Get the latest Bristol-Myers Squibb stock price and detailed information including BMY news, historical charts and realtime prices. No matter the role within BMS, we all embrace a patient-centric culture. Currency in USD Follow 2W 10W 9M 70.18 -1.22 (-1.71%) At close: 04:00PM EST 70.40 +0.22 (+0.31%) After hours: 07:43PM EST Time. Youll find valuable developmental opportunities to help connect you to your passion and drive your career forward. Bristol Myers Squibb Vacation & Paid Time Off 344 employees reported this benefit 4.4 54 Ratings Available to US-based employees Change location Employer Verified Mar 7, 2022 Employee Comments Showing 1-10 of 54 Jan 28, 2023 4.0 Current Direcror in nullnull Comparable to big Pharma company Helpful Report Dec 22, 2022 4.0 Required to work every rotating weekends, some holidays, and during adverse weather conditions in support of . Home; Our Services; About us; Blog; Contact Bristol-Myers Squibb (NYSE: BMY) is a global biopharmaceutical company committed to discovering, developing, and delivering medicines that help patients prevail over serious diseases. FOURTH QUARTER PRODUCT REVENUE HIGHLIGHTS, *In excess of +100%. The companys performance in the first quarter of 2021 Furthermore, one of the three required milestones for payment of the Bristol Myers Squibb Contingent Value Right (CVR) remained unaccomplished due to the pending FDA approval as of Dec. 31, 2020. . Bristol-Myers Squibb has 9 holidays and 4 personal/floating holidays. Its primary focus is on cancer, cardiovascular, immunology and fibrotic therapeutic projects. The financial guidance is subject to risks and uncertainties applicable to all forward-looking statements as described elsewhere in this communication. 0000000016 00000 n Learn more! We may also use social media channels to communicate with our investors and the public about our company, our products and other matters, and those communications could be deemed to be material information.